April 2023: Bristol Myers Squibb announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) suggested approval of CAMZYOS® (mavacamten) for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients. The European Commission (EC), which has the competence to approve medicines for the European Union (EU), will now assess the CHMP opinion.
July 2023: Novartis AG has revealed that the US Food and Drug Administration (FDA) has authorized a label update for Leqvio® (inclisiran) to allow for earlier usage as an addition to diet and statin therapy in patients with elevated LDL-C who are at increased risk of heart disease1. This patient group comprises patients with comorbidities such as hypertension and diabetes who have not yet experienced their first cardiovascular event. Leqvio is the first and only small interfering RNA (siRNA) medication to decrease LDL-C, and it was approved by the FDA in December 2021.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5386
Published Date: Nov 21, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The increasing need for early detection and growing development of gene therapies are the major factors driving the market growth.
The market size of genetic cardiomyopathies is anticipated to attain a CAGR of ~13% over the forecast period, i.e., 2024-2036.
The major players in the market are Novartis International AG, Merck & Co., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Mylan N.V., Boston Scientific Corporation, Critical Care Diagnostics Inc., Bio-Rad Laboratories Inc., Roche Holding AG, AstraZeneca PLC, and Sanofi S.A
The dilated cardiomyopathy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.